Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Coherus, Amgen Settle Patent Suit on Arthritis Biosimilar Drug

Nov. 26, 2019, 6:55 PM

Coherus and Amgen dropped a lawsuit in which Coherus claimed Amgen’s biosimilar of AbbVie’s blockbuster arthritis drug Humira infringes four patents for its own biosimilar version.

  • No further details were provided in a notice of agreement, approved Tuesday in federal court in Wilmington, Delaware
  • Amgen launched Amgevita, a biosimilar of Humira, in Europe in October 2018
    • Amgevita is sold only in Europe but is made in the U.S., which Coherus alleged as infringement of its patents
  • Biosimilars are nearly identical versions of branded biological drugs and are made from living organisms
  • Amgen’s U.S. version, called Amgevita, won’t come to market ...